Ubix Therapeutics

Biotechnology Research • 7 Beobwon-ro 11-gil, Songpa-gu, Korea, Republic of • 1-10 Employees

Company overview

Headquarters	7 Beobwon-ro 11-gil, Songpa-gu, C-dong, unit 1401, Seoul, Seoul 05836, KR
Phone number	+82263352475
Website	ubixtrx.com
NAICS	541714
SIC	283
Founded	2018
Employees	1-10
Socials

Key Contacts at Ubix Therapeutics

Hyun-Jin Yang

Director Of Business Development

Song Hee Lee

Research Director

Jong-Hwan Lim

Director Of Preclinical/Clinical Development

Jihye Lee

Director Of Open Innovation

About Ubix Therapeutics

Saving Lives Through Innovations in Targeted Protein Degradation (TPD) Therapeutics. Ubix Therapeutics is a clinical-stage biotechnology company with comprehensive capabilities in TPD therapeutics, spanning from discovery to clinical studies. Our proprietary TPD platform technology, Degraducer®, harnesses the body’s natural protein degradation machinery to eliminate diseased proteins, achieving near-complete inactivation of disease-causing pathways. We have established a robust, wholly owned and partnered degrader pipeline focused on targeted and immuno-oncology areas. Our wholly owned programs include: • UBX-303-1, a Phase 1-stage, potential best-in-class BTK degrader for treating relapsed or refractory B-cell malignancies. • UBX-106, a preclinical-stage, potential first-in-class SHP2 degrader designed to treat a broad spectrum of MAPK signaling-driven solid tumors. Additionally, the IND-enabling study for UBX-103, AR degrader program which was out-licensed to Yuhan in July 2024, is currently underway. We believe our degrader programs can effectively address a broad range of drug resistance mutations and overcome residual activation of disease-causing signaling pathways. Our growing pipeline also includes programs targeting difficult-to-address proteins and the development of degrader-antibody conjugates. For more information, please visit http://en.ubixtrx.com/ or contact us at info@ubixtrx.com.

Ubix Therapeutics revenue & valuation

Annual revenue	$769,995
Revenue per employee	$86,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$2,500,000
Total funding	$35,400,000

Employees by Management Level

Total employees: 1-10

Seniority

Employees

Director

Entry

Employees by Department

Ubix Therapeutics has 3 employees across 3 departments.

Departments

Number of employees

Funding Data

Explore Ubix Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount
2022-02-01	5	N/A
2025-01-23	1	$17,700,000
2025-01-23	6	$17,700,000

Funding Insights

$35,400,000

Total funding amount

$17,700,000

Most recent funding amount

Number of funding rounds

Frequently asked questions

Ubix Therapeutics is located in 7 Beobwon-ro 11-gil, Songpa-gu, KR.

You can reach Ubix Therapeutics at +82263352475.

Ubix Therapeutics was founded in 2018, making it 8 years old. The company has established itself as a significant player in its industry over this time.

Ubix Therapeutics has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.

Ubix Therapeutics has raised a total of $35,400,000 across 3 funding rounds. This investment has helped the company grow and expand its operations.